Veraxa Biotech Shares Drop 55.32% to $9.46 on Nasdaq Debut
VRXA•Veraxa Biotech AG shares plunged $11.76, or 55.32%, to $9.46 during its initial Nasdaq Capital Market trading days. The company, which completed a business combination with Voyager Acquisition Corp, is developing bispecific T-cell engagers and antibody-drug conjugates for cancer but saw heavy post-listing volatility.
1. Post-Listing Volatility Drives Sharp Decline
Veraxa Biotech AG shares fell $11.76, or 55.32%, to $9.46 in early Nasdaq trading, leading declines among healthcare and biotech names. The selloff appears linked to volatility following its recent listing rather than any specific operational update.
2. Business Combination and Pipeline Overview
Veraxa completed a business combination with Voyager Acquisition Corp to begin trading on the Nasdaq Capital Market. The company is advancing next-generation cancer therapies, including bispecific T-cell engagers and antibody-drug conjugates, positioning it in the competitive oncology immunotherapy field.
